[go: up one dir, main page]

PL2089060T3 - Preparat ciekły zawierający kompleks pimobendanu i cyklodekstryny - Google Patents

Preparat ciekły zawierający kompleks pimobendanu i cyklodekstryny

Info

Publication number
PL2089060T3
PL2089060T3 PL07822208T PL07822208T PL2089060T3 PL 2089060 T3 PL2089060 T3 PL 2089060T3 PL 07822208 T PL07822208 T PL 07822208T PL 07822208 T PL07822208 T PL 07822208T PL 2089060 T3 PL2089060 T3 PL 2089060T3
Authority
PL
Poland
Prior art keywords
pimobendan
cyclodextrin
complex
liquid preparation
preparation
Prior art date
Application number
PL07822208T
Other languages
English (en)
Inventor
Martin A Folger
Stefan Lehner
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of PL2089060T3 publication Critical patent/PL2089060T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL07822208T 2006-11-07 2007-11-05 Preparat ciekły zawierający kompleks pimobendanu i cyklodekstryny PL2089060T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06123567A EP1920785A1 (en) 2006-11-07 2006-11-07 Liquid preparation comprising a complex of pimobendan and cyclodextrin
PCT/EP2007/061879 WO2008055871A1 (en) 2006-11-07 2007-11-05 Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP07822208.0A EP2089060B1 (en) 2006-11-07 2007-11-05 Liquid preparation comprising a complex of pimobendan and cyclodextrin

Publications (1)

Publication Number Publication Date
PL2089060T3 true PL2089060T3 (pl) 2014-11-28

Family

ID=37735786

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07822208T PL2089060T3 (pl) 2006-11-07 2007-11-05 Preparat ciekły zawierający kompleks pimobendanu i cyklodekstryny
PL14171537T PL2789349T3 (pl) 2006-11-07 2007-11-05 Ciekły preparat zawierający pimobendan

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14171537T PL2789349T3 (pl) 2006-11-07 2007-11-05 Ciekły preparat zawierający pimobendan

Country Status (23)

Country Link
US (3) US9107952B2 (pl)
EP (3) EP1920785A1 (pl)
JP (1) JP5565794B2 (pl)
KR (1) KR101434324B1 (pl)
CN (3) CN104800153A (pl)
AR (1) AR063587A1 (pl)
AU (1) AU2007316712B2 (pl)
BR (1) BRPI0718541B8 (pl)
CA (1) CA2668733C (pl)
CL (1) CL2007003201A1 (pl)
CY (1) CY1115710T1 (pl)
DK (2) DK2089060T3 (pl)
ES (2) ES2649718T3 (pl)
HR (1) HRP20140873T1 (pl)
HU (1) HUE035821T2 (pl)
MX (1) MX2009004767A (pl)
NZ (1) NZ577067A (pl)
PL (2) PL2089060T3 (pl)
PT (1) PT2089060E (pl)
SI (1) SI2089060T1 (pl)
TW (1) TWI432425B (pl)
WO (1) WO2008055871A1 (pl)
ZA (1) ZA200902085B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2702987A1 (en) 2008-11-25 2014-03-05 Boehringer Ingelheim Vetmedica GmbH Phosphodiesterase type III (PDE III) inhibitors or Ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
NL1037569C2 (en) * 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
CA2930119C (en) 2010-10-19 2019-10-29 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
MX392972B (es) 2012-04-13 2025-03-21 L&F Res Llc Metodo para utilizar ciclodextrina.
WO2015007759A1 (en) * 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EP3865120B1 (en) 2013-07-19 2025-06-25 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
WO2015082389A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
WO2017159585A1 (ja) * 2016-03-14 2017-09-21 参天製薬株式会社 メグルミン又はその塩からなる防腐剤
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
KR101829685B1 (ko) * 2016-07-28 2018-02-19 씨제이헬스케어 주식회사 안정성 및 용해도가 개선된 주사용 조성물
CN106729723A (zh) * 2016-11-21 2017-05-31 青岛农业大学 一种含匹莫苯丹的药物组合物及其制备方法
KR102034760B1 (ko) 2018-12-31 2019-10-22 지앤에스건설 주식회사 긴장시스템을 도입한 일체형 현장타설 말뚝 시공방법이 적용된 구조
US20210177842A1 (en) * 2019-10-23 2021-06-17 Piedmont Animal Health Inc. Pimobendan formulation and method of use thereof
WO2022073954A1 (en) 2020-10-08 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan in the anaesthesia of non-human mammals
KR102546153B1 (ko) 2022-08-01 2023-06-20 함정아 횡방향 지지력이 증가된 교량용 말뚝 및 그 시공방법
JP2025539571A (ja) 2022-12-15 2025-12-05 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 非晶質ピモベンダン及び1種又は複数の安定化ポリマーを含む固体分散体

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1045031A (en) 1963-04-30 1966-10-05 Iwao Kawakami Dentifrice
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3574859A (en) 1968-07-05 1971-04-13 Carl M Kosti Process for the treatment of hypertrophied gums
US3822349A (en) 1969-06-02 1974-07-02 C Kosti Vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
CA950833A (en) 1971-02-02 1974-07-09 Carl M. Kosti Composition for the treatment of hypertrophied oral tissue
GB1338169A (en) 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
US3832460A (en) 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
US3839522A (en) 1971-08-02 1974-10-01 Batley Janss Enterprises Process for the manufacture of dog bedding
CH630808A5 (en) 1976-05-08 1982-07-15 Uscio Heinz D Process for aromatising pharmaceutical preparations for veterinary medicine
GB1565966A (en) 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
ES482789A0 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
DE2841668A1 (de) 1978-09-25 1980-04-10 Bayer Ag Medikiertes tierfutter auf basis lebermehl
US4256743A (en) 1979-02-22 1981-03-17 President And Fellows Of Harvard College Inhibition of bone resorption with H1 -blocking antihistamines
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4293557A (en) 1979-07-03 1981-10-06 Teikoku Hormone Mfg. Co., Ltd. Antiulcer phenoxypropylamine derivatives
US4375547A (en) 1980-10-02 1983-03-01 Eli Lilly And Company N-Methyl-N'-2-([(2-dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine
IT1209431B (it) 1980-11-28 1989-07-16 Angeli Inst Spa Imidazolilfenil amidine, processi per la loro preparazione e loro impiego farmaceutico, ed intermedi di preparazione.
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
US4704284A (en) 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8313217D0 (en) 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
JPS59222406A (ja) 1983-06-01 1984-12-14 Teijin Ltd 歯周疾患治療用製剤及びその製造法
US4732915A (en) 1983-11-02 1988-03-22 Alza Corporation Process for increasing solubility of drug
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8400863D0 (en) 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
ES2031821T3 (es) 1985-10-17 1993-01-01 Smith Kline & French Laboratories Limited Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
JPH0759496B2 (ja) 1986-03-25 1995-06-28 ロ−ト製薬株式会社 歯周病治療剤
JPS62223112A (ja) 1986-03-25 1987-10-01 Rooto Seiyaku Kk 歯周病治療剤
IT1204901B (it) 1986-06-25 1989-03-10 Iscofar Sas Composizioni contenenti acido usnico o suoi derivati atte all'impiego nel trattamento della carie dentaria
ZA878182B (en) 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
US4868182A (en) 1986-11-05 1989-09-19 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3728244A1 (de) 1987-08-25 1989-03-09 Thomae Gmbh Dr K Neue (-)-benzimidazole, deren herstellung und diese verbindungen enthaltende arzneimittel
EP0306846A3 (de) 1987-09-11 1990-05-02 Dr. Karl Thomae GmbH Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
SE8704436D0 (sv) 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DE3804490A1 (de) 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
IE62095B1 (en) 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
ES2058503T5 (es) * 1988-03-29 1999-04-16 Univ Florida Formulaciones farmaceuticas para uso parenteral.
EP0349657A1 (en) 1988-06-06 1990-01-10 Carl Richard Thornfeldt Manufacture of a medicament for the treatment of teething and colic
GB8824458D0 (en) 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
US5364646A (en) 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
DE4001622A1 (de) 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
DE4001623A1 (de) 1990-01-20 1991-07-25 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen geeigneten arzneimittels
US5188836A (en) 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
JPH0489428A (ja) 1990-07-30 1992-03-23 Kao Corp 多形核白血球活性化剤
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
JPH0570612A (ja) * 1991-09-12 1993-03-23 Toyobo Co Ltd 二軸配向ポリエステルフイルム
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
JPH10501211A (ja) 1994-05-20 1998-02-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 飼育動物用のチュワブル・フルベンダゾール錠剤
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
JPH11228302A (ja) 1998-02-18 1999-08-24 Taisho Technos Co Ltd 抗菌防黴組成物
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
CA2342797A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
ATE264104T1 (de) 1998-10-23 2004-04-15 Toray Industries Immunmodulierende arzneimittelzusammenstellung
PT1178778E (pt) 1999-05-17 2006-06-30 D B F Granulos que contem uma substancia vegetal e o seu procedimento de preparacao
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
GB2356346A (en) 1999-11-19 2001-05-23 Mars Uk Ltd Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product
KR100784752B1 (ko) 2000-02-04 2007-12-13 다케다 야쿠힌 고교 가부시키가이샤 안정한 에멀젼 조성물
EP1260215B1 (en) 2000-03-01 2009-07-29 Eisai R&D Management Co., Ltd. Rapidly disintegrable tablet containing polyvinyl alcohol
WO2001097861A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
CN1461218A (zh) 2000-12-18 2003-12-10 诺瓦提斯公司 阿洛地平和贝那普利的治疗组合
EP1247456A3 (en) 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
JP2005511475A (ja) * 2001-03-02 2005-04-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
DE60237696D1 (de) 2001-08-01 2010-10-28 Univ Utah Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
CA2463687A1 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
AU2003218059A1 (en) 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
CO5400144A1 (es) 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
AR040017A1 (es) 2002-05-17 2005-03-09 Novartis Ag Combinacion de compuestos organicos
JP2005529927A (ja) 2002-05-23 2005-10-06 ファイザー インコーポレイテッド 新規な組み合わせ
SI21223A (sl) 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US20040037869A1 (en) 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
KR20050070036A (ko) 2002-10-07 2005-07-05 아티젼 쎄라퓨틱스, 인크. L형 칼슘 채널을 차단하는 동시에 3형포스포디에스테라제의 활성을 억제할 수 있는디히드로피리딘 화합물
WO2004050657A2 (en) 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
CA2511385A1 (en) 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
WO2004058726A2 (en) 2002-12-23 2004-07-15 Artesian Therapeutics, Inc. CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
US20050085446A1 (en) 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
WO2005008467A1 (ja) 2003-07-22 2005-01-27 Gunze Limited 透明タッチパネル及び電子機器
WO2005035505A2 (en) 2003-09-30 2005-04-21 Artesian Therapeutics, Inc. Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
JP2005281283A (ja) * 2004-03-31 2005-10-13 Akira Matsumori ベンズイミダゾール系薬剤の併用医薬
MXPA06012777A (es) 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
FI20040675A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
CN1698636A (zh) * 2004-05-17 2005-11-23 王玉万 兽用抗寄生虫制剂的混用方法
AU2005256322C1 (en) 2004-06-28 2011-07-07 Veloxis Pharmaceuticals, Inc. Porous tablets as carriers for liquid formulations
NZ534939A (en) * 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
EP1833480A2 (en) 2004-11-30 2007-09-19 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
US20080090827A1 (en) 2004-11-30 2008-04-17 Artesian Therapeutics, Inc. Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
CN1702243A (zh) 2005-05-31 2005-11-30 刘坚雄 无壁板框架结构装配组合式房屋建筑及其建造方法
US20090036406A1 (en) * 2005-06-13 2009-02-05 Takeda Pharmaceutical Company Limited Injection
WO2007038796A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CN101309685A (zh) 2005-11-14 2008-11-19 贝林格尔·英格海姆维特梅迪卡有限公司 磷酸二酯酶ⅲ型抑制剂或者钙增敏剂用于治疗无症状(潜隐性)心力衰竭的用途
JP4572300B2 (ja) 2006-01-19 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
EP2003970A4 (en) 2006-03-28 2012-07-11 Javelin Pharmaceuticals Inc FORMULATIONS OF LOW-DOSEED NON-STEROID INFLAMMATORY INHIBITORS AND BETA-CYCLODEXTRIN
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
EP2106786A1 (de) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
FR2934156B1 (fr) 2008-07-23 2010-09-24 Virbac Medicament appetissant a administration orale sous forme solide
WO2010055119A2 (en) 2008-11-17 2010-05-20 Novartis Ag Pharmaceutical composition comprising pimobendan
EP2702987A1 (en) 2008-11-25 2014-03-05 Boehringer Ingelheim Vetmedica GmbH Phosphodiesterase type III (PDE III) inhibitors or Ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
US20100166857A1 (en) 2008-12-30 2010-07-01 Dong Yan Pharmaceutical dosage forms and methods of manufacturing same
GB0912646D0 (en) 2009-07-21 2009-08-26 Jagotec Ag Improvements in or relating to organic compounds
CN102264372B (zh) 2009-08-31 2012-07-11 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
EP2485716A2 (en) 2009-10-07 2012-08-15 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
NL1037569C2 (en) 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
EP2338480A1 (en) 2009-12-22 2011-06-29 LEK Pharmaceuticals d.d. Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt
JP5813391B2 (ja) 2011-06-24 2015-11-17 日東電工株式会社 粒子製剤の製造方法
US20120308662A1 (en) 2011-06-01 2012-12-06 Nitto Denko Corporation Particulate preparation and method for producing the same
AU2012296925A1 (en) 2011-08-12 2014-02-06 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
AU2012101682B4 (en) 2011-11-20 2013-10-24 Betrola Investments Pty Limited Formulation
EP2793866B2 (en) 2011-12-21 2023-10-25 Elanco Tiergesundheit AG Bilayer tablet comprising benazepril hydrochloride and pimobendan
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
GB201207886D0 (en) 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
SG11201407200TA (en) 2012-05-18 2014-12-30 Luoda Pharma Pty Ltd Liquid formulation
FR3002736B1 (fr) 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
EP3865120B1 (en) 2013-07-19 2025-06-25 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
WO2015082389A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Also Published As

Publication number Publication date
EP2789349B1 (en) 2017-09-06
US10639305B2 (en) 2020-05-05
US9616134B2 (en) 2017-04-11
CA2668733A1 (en) 2008-05-15
US9107952B2 (en) 2015-08-18
CY1115710T1 (el) 2017-01-25
TW200829571A (en) 2008-07-16
AU2007316712B2 (en) 2013-05-30
AU2007316712A1 (en) 2008-05-15
ES2500441T3 (es) 2014-09-30
CN104800153A (zh) 2015-07-29
DK2089060T3 (da) 2014-09-22
ES2649718T3 (es) 2018-01-15
CL2007003201A1 (es) 2008-04-11
JP2010508372A (ja) 2010-03-18
SI2089060T1 (sl) 2014-10-30
KR101434324B1 (ko) 2014-08-27
NZ577067A (en) 2012-02-24
EP1920785A1 (en) 2008-05-14
KR20090084925A (ko) 2009-08-05
US20170165260A1 (en) 2017-06-15
PT2089060E (pt) 2014-09-03
BRPI0718541A2 (pt) 2013-11-19
BRPI0718541B8 (pt) 2021-05-25
JP5565794B2 (ja) 2014-08-06
EP2089060A1 (en) 2009-08-19
HRP20140873T1 (hr) 2014-12-05
US20080207629A1 (en) 2008-08-28
DK2789349T3 (da) 2017-11-20
CN104688680A (zh) 2015-06-10
EP2089060B1 (en) 2014-06-25
MX2009004767A (es) 2009-05-21
HUE035821T2 (hu) 2018-05-28
AR063587A1 (es) 2009-02-04
BRPI0718541B1 (pt) 2020-09-15
PL2789349T3 (pl) 2018-02-28
CA2668733C (en) 2016-05-10
WO2008055871A1 (en) 2008-05-15
CN101534864A (zh) 2009-09-16
US20140235648A1 (en) 2014-08-21
TWI432425B (zh) 2014-04-01
ZA200902085B (en) 2010-04-28
EP2789349A1 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
ZA200902085B (en) Liquid preparation comprising a complex of pimobendan and cyclodextrin
IL198301A0 (en) Thiazole and oxazole-substituted arylamides
ZA200809582B (en) Fluid dispenser
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
PL2349863T3 (pl) Zawór i zawierający go dozownik
IL220270A0 (en) Polymyxin derivatives and uses thereof
EP2027136A4 (en) Large part cyclicxtrin inclusion complexes and method for their preparation
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
EP2081483A4 (en) ANTIEXTRAVASATIONSKATHETER
EP1978335A4 (en) FLOW METER
GB0707130D0 (en) Fluid dispenser
EP1977733A4 (en) LIQUID COSMETICS
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
GB0813961D0 (en) Swab
IL210163A0 (en) Pharmaceutical compositions comprising a complex of aminocyclohexane derivatives and cyclodextrin
PL2104545T3 (pl) Filtr do cieczy
EP2037854A4 (en) VOIDABLE PRODUCT
IL202297A0 (en) Valve and dispenser
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
PL2007495T3 (pl) Filtr płynu
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
GB0619240D0 (en) Reduction of alpha-halo ketones
EP2068877A4 (en) COMPOUNDS AND METHODS FOR MODULATING ANGIOGENESIS
IL176030A0 (en) Liquid colander-ladle
IL177114A0 (en) Disposable swab